Since then, ALK TKIs, such as crizotinib and alectinib, which were developed for the treatment of ALK+ NSCLC patients, have been approved for ALK+ ALCL treatment in the US and Japan, respectively. This evidence concerns the gene ALK and non-small cell lung carcinoma.